Key facts
- It has raised $10K; the latest was Seed Round in Feb 2025.
- Notable investors include Venture Kick, Fongit, University of Geneva.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Adoram Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Adoram Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Adoram Therapeutics
Developer of allosteric modulators designed to offer a validated cancer immunotherapy target. The company's modulators help to treat solid tumors based on small molecule immunotherapy to overcome limitations of previous drug generations in adenosine-rich tumors, enabling researchers to address unmet medical needs in the field of onco-immunology.
- Sector
- Healthcare
- HQ
- Lancy, Switzerland
- Founded
- 2022
- Website
- adoram.ch/
- Ownership
- Privately Held (backing)
Adoram Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Adoram Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Adoram Therapeutics in its N-PORT filings yet. We sweep new filings monthly.